Compare Stocks

Date Range: 

 NovacytOpen OrphanKaleido BiosciencesUnity BiotechnologyMedicenna Therapeutics
SymbolLON:NCYTLON:ORPHNASDAQ:KLDONASDAQ:UBXTSE:MDNA
Price Information
Current PriceGBX 419.20GBX 37.75$7.46$4.63C$4.46
52 Week RangeHoldN/ABuyHoldN/A
MarketRank™
Overall Score0.60.01.81.10.5
Analysis Score0.00.03.30.90.0
Community Score1.90.02.02.52.4
Dividend Score0.00.00.00.00.0
Ownership Score0.00.03.31.70.0
Earnings & Valuation Score1.30.00.60.60.0
Analyst Ratings
Consensus RecommendationHoldN/ABuyHoldN/A
Consensus Price TargetN/AGBX 19$17.90$4.80N/A
% Upside from Price TargetN/A-49.67% downside139.95% upside3.67% upsideN/A
Trade Information
Market Cap£296.06 million£252.70 million$317.19 million$253.67 millionC$235.94 million
BetaN/AN/A0.020.36N/A
Average Volume958,2673,185,557323,729687,821110,552
Sales & Book Value
Annual Revenue£78.23 million£10.57 millionN/AN/AN/A
Price / Sales3.7823.90N/AN/AN/A
CashflowGBX 30 per shareGBX 2.98 per shareN/AN/AC$0.63 per share
Price / Cash13.9712.65N/AN/A7.07
Book ValueGBX 89.40 per shareGBX 6 per shareN/AN/AC$0.68 per share
Price / Book0.050.06N/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSGBX 51.50GBX (3.20)($3.36)($1.88)C($0.31)
Trailing P/E Ratio8.14N/AN/AN/AN/A
Forward P/E RatioN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio3.86%20.36%N/AN/A0.12%
Current Ratio2.41%2.72%N/AN/A16.36%
Quick Ratio1.79%2.57%N/AN/A15.27%
Ownership Information
Institutional Ownership PercentageN/AN/A79.91%37.21%N/A
Insider Ownership PercentageN/AN/A10.00%37.30%N/A
Miscellaneous
Employees11013282617
Shares Outstanding70.63 million669.40 million42.52 million54.79 million52.90 million
Next Earnings DateN/A6/21/2021 (Estimated)8/3/2021 (Estimated)7/29/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent GlioblastomaMedicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma
finance.yahoo.com - May 7 at 9:21 AM
Medicenna to Present at the Bloom Burton & Co. Healthcare Investor ConferenceMedicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 14 at 9:25 AM
Medicenna Therapeutics Corp. (MDNA)Medicenna Therapeutics Corp. (MDNA)
realmoney.thestreet.com - January 10 at 10:22 PM
Dr. Fahar Merchant acquires shares of MedicennaDr. Fahar Merchant acquires shares of Medicenna
newswire.ca - January 7 at 12:22 PM
Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher TodayWhy Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today
msn.com - December 18 at 1:02 PM
Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In GrowthCompanies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth
finance.yahoo.com - December 4 at 10:42 AM
Medidata Synthetic Control Arm® Supported by the US Food and Drug Administration (FDA) for Use in Medicenna Therapeutics, Corp. Phase 3 Registrational Trial in Recurrent ...Medidata Synthetic Control Arm® Supported by the US Food and Drug Administration (FDA) for Use in Medicenna Therapeutics, Corp. Phase 3 Registrational Trial in Recurrent ...
businesswire.com - October 30 at 10:17 PM
Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)
markets.businessinsider.com - October 15 at 6:05 PM
Medicenna to Commence Trading on NasdaqMedicenna to Commence Trading on Nasdaq
finance.yahoo.com - August 20 at 6:42 PM
Medicenna Therapeutics Corp. (MDNAF)Medicenna Therapeutics Corp. (MDNAF)
ca.finance.yahoo.com - August 16 at 9:29 AM
MDNAF: End of Phase 2’ Meeting for MDNA55 in September 2020…MDNAF: End of Phase 2’ Meeting for MDNA55 in September 2020…
finance.yahoo.com - August 7 at 3:16 PM
Medicenna Reports First Quarter Fiscal 2021 Financial Results and Operational HighlightsMedicenna Reports First Quarter Fiscal 2021 Financial Results and Operational Highlights
finance.yahoo.com - August 4 at 8:04 AM
Medicenna to Present at Raymond James Human Healthcare Innovation ConferenceMedicenna to Present at Raymond James Human Healthcare Innovation Conference
finance.yahoo.com - June 11 at 10:04 AM
Are Insiders Buying Medicenna Therapeutics Corp. (TSE:MDNA) Stock?Are Insiders Buying Medicenna Therapeutics Corp. (TSE:MDNA) Stock?
finance.yahoo.com - June 7 at 12:20 PM
MDNA.TO: New Data for MDNA55 and MDNA11 Presented at ASCO 2020…MDNA.TO: New Data for MDNA55 and MDNA11 Presented at ASCO 2020…
finance.yahoo.com - June 3 at 5:19 PM
Medicenna Therapeutics (MDNAF) Presents supplementary data for MDNA55 and MDNA11 at ASCO 2020 - SlideshowMedicenna Therapeutics (MDNAF) Presents supplementary data for MDNA55 and MDNA11 at ASCO 2020 - Slideshow
seekingalpha.com - June 1 at 8:13 PM
Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020Medicenna Updates Efficacy Results from Phase 2b Recurrent GBM Trial at ASCO 2020
finance.yahoo.com - May 29 at 1:08 PM
Medicenna, Northern Dynasty at 52-Week Highs on NewsMedicenna, Northern Dynasty at 52-Week Highs on News
www.baystreet.ca - May 29 at 1:08 PM
Medicenna has lots left in the tank, says Bloom BurtonMedicenna has lots left in the tank, says Bloom Burton
www.cantechletter.com - May 26 at 7:26 PM
MDNA.TO: Data on MDNA55 and MDNA11 to be Presented at ASCO 2020…MDNA.TO: Data on MDNA55 and MDNA11 to be Presented at ASCO 2020…
finance.yahoo.com - May 20 at 1:38 PM
BRIEF-Medicenna Therapeutics Expect To Complete IND Enabling Studies For MDNA109 Superkine Platform By Q1BRIEF-Medicenna Therapeutics Expect To Complete IND Enabling Studies For MDNA109 Superkine Platform By Q1
uk.reuters.com - May 17 at 12:56 AM
Medicenna Announces March 31, 2020 Year-End ResultsMedicenna Announces March 31, 2020 Year-End Results
finance.yahoo.com - May 15 at 8:20 AM
Medicenna Announces Upcoming Presentations at the ASCO Annual MeetingMedicenna Announces Upcoming Presentations at the ASCO Annual Meeting
finance.yahoo.com - May 4 at 7:05 AM
Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public OfferingMedicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public Offering
finance.yahoo.com - April 15 at 9:36 AM
MDNA.TO: ENCOURAGING MDNA19 DATA IN NON-HUMAN PRIMATES; FINANCING FUNDS COMPANY THROUGH END OF 2022…MDNA.TO: ENCOURAGING MDNA19 DATA IN NON-HUMAN PRIMATES; FINANCING FUNDS COMPANY THROUGH END OF 2022…
finance.yahoo.com - March 30 at 7:56 PM
DateCompanyBrokerageAction
3/11/2021NovacytOddo BhfInitiated Coverage
3/11/2021NovacytOddo SecuritiesInitiated Coverage
7/28/2020Open OrphanFinnCapReiterated Rating
3/15/2021Kaleido BiosciencesMorgan StanleyLower Price Target
3/4/2021Kaleido BiosciencesCanaccord GenuityReiterated Rating
2/9/2021Kaleido BiosciencesPiper SandlerInitiated Coverage
1/14/2021Kaleido BiosciencesChardan CapitalBoost Price Target
12/23/2020Kaleido BiosciencesJMP SecuritiesInitiated Coverage
10/14/2020Kaleido BiosciencesJPMorgan Chase & Co.Initiated Coverage
3/25/2019Kaleido BiosciencesThe Goldman Sachs GroupInitiated Coverage
3/26/2021Unity BiotechnologyMizuhoBoost Price Target
2/16/2021Unity BiotechnologyCitigroupDowngrade
8/17/2020Unity BiotechnologyRoth CapitalDowngrade
12/12/2019Unity BiotechnologyCantor FitzgeraldReiterated Rating
11/19/2019Medicenna TherapeuticsBrookline Capital ManagementReiterated Rating
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.